Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.92 -0.30 (-1.10%)
Official Closing Price Updated: 7:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Better Buy Right Now: Johnson & Johnson Vs. Pfizer ↗
The choice is based on more than just the dividend payout. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
A Healthcare Stock With a 6%-Plus Yield: Is the Dividend Safe? ↗
The company has increased its payouts over the past five years despite significant challenges. 
Via The Motley Fool
News headline image
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
Via MarketMinute
Topics Bonds
News headline image
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Telix Strengthens Board with Additional Director Appointments
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the... 
Via MarketMinute
News headline image
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma... 
Via Newsfile
News headline image
Why Pfizer Stock Tumbled on Tuesday ↗
One analyst reiterated his pessimistic view of the pharmaceutical titan's future. 
Via The Motley Fool
Topics Intellectual Property
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Why Is Pfizer Stock Dropping Tuesday? ↗
Pfizer Inc (NYSE:PFE) shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot trial. 
Via Benzinga
News headline image
Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today ↗
The healthcare stock looks ridiculously undervalued. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
From AINewsWire
Via GlobeNewswire
News headline image
Covered Call Screener Results for April 7th
Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase. 
Via Barchart.com
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
Via MarketMinute
News headline image
S&P 500 Snaps Five-Week Slump with 3.4% Tech-Led Surge Amid Middle East De-escalation Hopes
The S&P 500 (NYSEARCA:SPY) concluded the week ending April 4, 2026, with a resounding 3.4% rally, marking its strongest weekly performance since late 2025. This surge effectively halted a grueling... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
2 Healthcare Stocks for Long-Term Investors and 1 We Ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects... 
Via StockStory
News headline image
2 Reasons to Watch PFE and 1 to Stay Cautious
Even during a down period for the markets, Pfizer has gone against the grain, climbing to $28.30. Its shares have yielded a 7.1% return over the last six mon... 
Via StockStory
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff... 
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require... 
Via MarketMinute
Topics Economy
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Monster Dividend Stocks to Hold for the Next 10 Years ↗
These are great and steady income providers for your portfolio. 
Via The Motley Fool
News headline image
Pfizer, BioNTech Hit Pause On COVID Shot Trial As Enrollment Falls Flat ↗
Pfizer & BioNTech halt recruitment for a major U.S. COVID vaccine trial for adults 50–64 due to low enrollment. Read the latest updates. 
Via Benzinga
News headline image
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges ↗
The company said its prostate cancer drug showed comparable effectiveness to a rival in the class. 
Via Investor's Business Daily
Which S&P500 stocks are the most active on Tuesday? ↗
Via Chartmill
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
Prediction: Buying Pfizer Stock Today Could Set You Up for Life ↗
Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Reason This Biotech Stock Could Triple Before Year-End ↗
This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.